- Home
- PLX vs VOR Comparison
PLX vs VOR Comparison
Compare PLX & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- VOR
- Stock Information
- Founded
- PLX 1993
- VOR 2015
- Country
- PLX United States
- VOR United States
- Employees
- PLX N/A
- VOR N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- PLX Health Care
- VOR Health Care
- Exchange
- PLX Nasdaq
- VOR Nasdaq
- Market Cap
- PLX 204.9M
- VOR 207.1M
- IPO Year
- PLX 1998
- VOR 2021
- Fundamental
- Price
- PLX $2.19
- VOR $18.94
- Analyst Decision
- PLX Strong Buy
- VOR Buy
- Analyst Count
- PLX 1
- VOR 6
- Target Price
- PLX $15.00
- VOR $84.00
- AVG Volume (30 Days)
- PLX 934.1K
- VOR 392.4K
- Earning Date
- PLX 11-13-2025
- VOR 11-07-2025
- Dividend Yield
- PLX N/A
- VOR N/A
- EPS Growth
- PLX N/A
- VOR N/A
- EPS
- PLX 0.08
- VOR N/A
- Revenue
- PLX $61,948,000.00
- VOR N/A
- Revenue This Year
- PLX $14.53
- VOR N/A
- Revenue Next Year
- PLX $75.77
- VOR N/A
- P/E Ratio
- PLX $28.28
- VOR N/A
- Revenue Growth
- PLX 62.79
- VOR N/A
- 52 Week Low
- PLX $1.16
- VOR $2.62
- 52 Week High
- PLX $3.10
- VOR $65.80
- Technical
- Relative Strength Index (RSI)
- PLX 46.99
- VOR 34.54
- Support Level
- PLX $2.25
- VOR $19.62
- Resistance Level
- PLX $2.40
- VOR $26.76
- Average True Range (ATR)
- PLX 0.14
- VOR 2.09
- MACD
- PLX -0.02
- VOR -1.28
- Stochastic Oscillator
- PLX 40.70
- VOR 9.23
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.